CAS: 14047-26-8 - 9H-Purine-9-ethanol, 6-amino-a-methyl-
Formula:C8H11N5O
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | 9H-Purine-9-ethanol, 6-amino-α-methyl- REF: IN-DA001CIMCAS: 14047-26-8 | - - - | To inquire | Thu 12 Dec 24 |
 | 9-(2-Hydroxypropyl)adenine REF: TR-H952010CAS: 14047-26-8 | - - - | 212.00 €~860.00 € | Thu 02 Jan 25 |
| 9-(2-Hydroxypropyl)adenine-13C5 REF: TR-H952012CAS: 14047-26-8 | - - - | 1,589.00 € | Wed 22 Jan 25 |
 | 9-(2-Hydroxypropyl)adenine REF: 3D-PAA04726CAS: 14047-26-8 | Min. 95% | - - - | Discontinued product |
9H-Purine-9-ethanol, 6-amino-α-methyl-
CAS:14047-26-8
Formula:
C8H11N5O
Color and Shape:
Solid
Molecular weight:
193.2058
Ref: IN-DA001CIM
| Undefined size | To inquire |
Estimated delivery in United States, on Thursday 12 Dec 2024
9-(2-Hydroxypropyl)adenine
Controlled ProductCAS:14047-26-8
Applications 9-(2-Hydroxypropyl)adenine is the unlabeled form of 9-(2-Hydroxypropyl)adenine-13C5 (H952012), which is an intermediate used in …
Formula:
C8H11N5O
Color and Shape:
Neat
Molecular weight:
193.21
Ref: TR-H952010
| 1mg | 212.00 € | ||
| 5mg | 860.00 € | ||
| 2500µg | 468.00 € |
Estimated delivery in United States, on Thursday 2 Jan 2025
9-(2-Hydroxypropyl)adenine-13C5
Controlled ProductCAS:14047-26-8
Applications 9-(2-Hydroxypropyl)adenine-13C5 is an intermediate used in the synthesis of rac Tenofovir-13C5 (>90%) (T018501), …
Formula:
C5C3H11N5O
Color and Shape:
Neat
Molecular weight:
198.169
Ref: TR-H952012
| 5mg | 1,589.00 € |
Estimated delivery in United States, on Wednesday 22 Jan 2025
9-(2-Hydroxypropyl)adenine
CAS:14047-26-8
Please enquire for more information about 9-(2-Hydroxypropyl)adenine including the price, delivery time and more detailed …
Formula:
C8H11N5O
Purity:
Min. 95%
Molecular weight:
193.21 g/mol
Ref: 3D-PAA04726
| 1mg | Discontinued | Request information | |
| 5mg | Discontinued | Request information | |
| 10mg | Discontinued | Request information | |
| 25mg | Discontinued | Request information | |
| 50mg | Discontinued | Request information |
